Javier Garde-Noguera1, M Leonor Fernández-Murga1, Vicent Giner-Bosch2, Victoria Dominguez-Márquez3, José García Sánchez1, Juan José Soler-Cataluña4, Franscica López Chuliá5, Beatriz Honrubia1, Nuria Piera1, Antonio Llombart-Cussac1,6,7,8. 1. Medical Oncology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), 46020 Valencia, Spain. 2. Centre For Quality and Change Management, Universitat Politècnica de València, 46022 Valencia, Spain. 3. Microbiology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), 46020 Valencia, Spain. 4. Pneumology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), 46020 Valencia, Spain. 5. Hematology Department, Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), Medicine Department, Cardenal Herrera University, 46020 Valencia, Spain. 6. Universidad Catolica de Valencia "San Vicente Martir", 46020 Valencia, Spain. 7. Medica Scientia Innovation Research (MedSIR), 08018 Barcelona, Spain. 8. Medica Scientia Innovation Research (MedSIR), Ridgewood, NJ 07450, USA.
Abstract
BACKGROUND: Studies of patients with cancer affected by coronavirus disease 2019 (COVID-19) are needed to assess the impact of the disease in this sensitive population, and the influence of different cancer treatments on the COVID-19 infection and seroconversion. MATERIAL AND METHODS: We performed a retrospective analysis of all patients hospitalized with RT-PCR positive for COVID-19 in our region to assess the prevalence of cancer patients and describe their characteristics and evolution (Cohort 1). Concurrently, a transversal study was carried out in patients on active systemic cancer treatment for symptomatology and seroprevalence (IgG/IgM by ELISA-method) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Cohort 2). RESULTS: A total of 215 patients (Cohort 1) were admitted to hospital with a confirmed COVID-19 infection between February 28 and April 30, 2020, and 17 died (7.9%). A medical record of cancer was noted in 43 cases (20%), 6 of them required Intensive care unit ICU attention (14%), and 7 died (16%). There were thirty-six patients (83%) who tested IgG/IgM positive for SARS-CoV-2. Patients on immunosuppressive therapies presented a lower ratio of seroconversion (40% vs. 8%; p = 0.02). In Cohort 2, 166 patients were included in a symptoms-survey and tested for SARS-CoV-2. Any type of potential COVID-19-related symptom was referred up to 67.4% of patients (85.9% vs. 48.2% vs. 73.9%, for patients on chemotherapy, immunotherapy and targeted therapies respectively, p < 0.05). The seroprevalence ratio was 1.8% for the whole cohort with no significant differences by patient or treatment characteristics. CONCLUSION: Patients with cancer present higher risks for hospital needs for COVID-19 infection. The lack of SARS-CoV-2 seroconversion may be a concern for patients on immunosuppressive therapies. Patients receiving systematic therapies relayed a high rate of potentially COVID-19-related symptoms, particularly those receiving chemotherapy. However, the seroconversion rate remains low and in the range of general population.
BACKGROUND: Studies of patients with cancer affected by coronavirus disease 2019 (COVID-19) are needed to assess the impact of the disease in this sensitive population, and the influence of different cancer treatments on the COVID-19infection and seroconversion. MATERIAL AND METHODS: We performed a retrospective analysis of all patients hospitalized with RT-PCR positive for COVID-19 in our region to assess the prevalence of cancerpatients and describe their characteristics and evolution (Cohort 1). Concurrently, a transversal study was carried out in patients on active systemic cancer treatment for symptomatology and seroprevalence (IgG/IgM by ELISA-method) against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Cohort 2). RESULTS: A total of 215 patients (Cohort 1) were admitted to hospital with a confirmed COVID-19infection between February 28 and April 30, 2020, and 17 died (7.9%). A medical record of cancer was noted in 43 cases (20%), 6 of them required Intensive care unit ICU attention (14%), and 7 died (16%). There were thirty-six patients (83%) who tested IgG/IgM positive for SARS-CoV-2. Patients on immunosuppressive therapies presented a lower ratio of seroconversion (40% vs. 8%; p = 0.02). In Cohort 2, 166 patients were included in a symptoms-survey and tested for SARS-CoV-2. Any type of potential COVID-19-related symptom was referred up to 67.4% of patients (85.9% vs. 48.2% vs. 73.9%, for patients on chemotherapy, immunotherapy and targeted therapies respectively, p < 0.05). The seroprevalence ratio was 1.8% for the whole cohort with no significant differences by patient or treatment characteristics. CONCLUSION:Patients with cancer present higher risks for hospital needs for COVID-19infection. The lack of SARS-CoV-2 seroconversion may be a concern for patients on immunosuppressive therapies. Patients receiving systematic therapies relayed a high rate of potentially COVID-19-related symptoms, particularly those receiving chemotherapy. However, the seroconversion rate remains low and in the range of general population.
Authors: B Rousseau; P Loulergue; O Mir; A Krivine; S Kotti; E Viel; T Simon; A de Gramont; F Goldwasser; O Launay; C Tournigand Journal: Ann Oncol Date: 2011-05-16 Impact factor: 32.976
Authors: Vincent J Munster; Marion Koopmans; Neeltje van Doremalen; Debby van Riel; Emmie de Wit Journal: N Engl J Med Date: 2020-01-24 Impact factor: 91.245
Authors: Sander van Assen; Albert Holvast; Cornelis A Benne; Marcel D Posthumus; Miek A van Leeuwen; Alexandre E Voskuyl; Marlies Blom; Anke P Risselada; Aalzen de Haan; Johanna Westra; Cees G M Kallenberg; Marc Bijl Journal: Arthritis Rheum Date: 2010-01
Authors: Nicole M Kuderer; Toni K Choueiri; Dimpy P Shah; Yu Shyr; Samuel M Rubinstein; Donna R Rivera; Sanjay Shete; Chih-Yuan Hsu; Aakash Desai; Gilberto de Lima Lopes; Petros Grivas; Corrie A Painter; Solange Peters; Michael A Thompson; Ziad Bakouny; Gerald Batist; Tanios Bekaii-Saab; Mehmet A Bilen; Nathaniel Bouganim; Mateo Bover Larroya; Daniel Castellano; Salvatore A Del Prete; Deborah B Doroshow; Pamela C Egan; Arielle Elkrief; Dimitrios Farmakiotis; Daniel Flora; Matthew D Galsky; Michael J Glover; Elizabeth A Griffiths; Anthony P Gulati; Shilpa Gupta; Navid Hafez; Thorvardur R Halfdanarson; Jessica E Hawley; Emily Hsu; Anup Kasi; Ali R Khaki; Christopher A Lemmon; Colleen Lewis; Barbara Logan; Tyler Masters; Rana R McKay; Ruben A Mesa; Alicia K Morgans; Mary F Mulcahy; Orestis A Panagiotou; Prakash Peddi; Nathan A Pennell; Kerry Reynolds; Lane R Rosen; Rachel Rosovsky; Mary Salazar; Andrew Schmidt; Sumit A Shah; Justin A Shaya; John Steinharter; Keith E Stockerl-Goldstein; Suki Subbiah; Donald C Vinh; Firas H Wehbe; Lisa B Weissmann; Julie Tsu-Yu Wu; Elizabeth Wulff-Burchfield; Zhuoer Xie; Albert Yeh; Peter P Yu; Alice Y Zhou; Leyre Zubiri; Sanjay Mishra; Gary H Lyman; Brian I Rini; Jeremy L Warner Journal: Lancet Date: 2020-05-28 Impact factor: 79.321
Authors: L Zhang; F Zhu; L Xie; C Wang; J Wang; R Chen; P Jia; H Q Guan; L Peng; Y Chen; P Peng; P Zhang; Q Chu; Q Shen; Y Wang; S Y Xu; J P Zhao; M Zhou Journal: Ann Oncol Date: 2020-03-26 Impact factor: 32.976
Authors: Stephen M Kissler; Christine Tedijanto; Yonatan H Grad; Marc Lipsitch; Edward Goldstein Journal: Science Date: 2020-04-14 Impact factor: 47.728
Authors: Mengni Guo; Jieying Liu; Shuntai Zhou; James Yu; Zohaib Ahmed; Sarfraz Ahmad; Manoucher Manoucheri; Mark A Socinski; Tarek Mekhail; Vincent Hsu Journal: SN Compr Clin Med Date: 2022-08-26